Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors have become a standard of care option for the treatment of patients with advanced melanoma. Since the approval of the first immune checkpoint (CTLA-4) inhibitor ipilimumab in 2011 and programmed death-1 (PD-1) blocking monoclonal antibodies pembrolizumab and nivolumab th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogiers, Anne, Boekhout, Annelies, Schwarze, Julia K., Awada, Gil, Blank, Christian U., Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512024/
https://www.ncbi.nlm.nih.gov/pubmed/31182961
http://dx.doi.org/10.1155/2019/5269062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512024/
https://www.ncbi.nlm.nih.gov/pubmed/31182961
http://dx.doi.org/10.1155/2019/5269062

Ejemplares similares